Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siltuximab Prophylaxis for CAR-T Associated CRS
NCT05665725Phase 1Completed
- Start
- Jan 2023
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of siltuximab in cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Primary endpoint: Frequency and nature of adverse events associated with siltuximab prophylaxis. Started Jan 2023; status: completed.
02
Drugs
siltuximab
03
Conditions
cytokine release syndrome (CRS)immune effector cell-associated neurotoxicity syndrome (ICANS)
Beyond the preview
Go deeper on NCT05665725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05665725.